相关实验视频
Updated: Jan 17, 2026

06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
1.6K
塞拉托格雷尔:有可能重新定义及时的抗血小板干预措施
Rudy N Zalzal1, Peter P Salem1, Ali H Dakroub2
1Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
British journal of pharmacology
|September 20, 2025
概括
塞拉托格雷尔是一种新的P2Y12抗剂,可为急性冠状动脉综合征 (ACS) 提供快速的皮下干预. 它的有利概况表明,有可能在医院前进行自我管理,减少缺血时间.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 急性冠状动脉综合征 (ACS) 是一个重要的心血管疾病负担.
- 目前用于ACS的双抗血小板疗法 (DAPT) 具有药理动力学和药理动力学限制.
研究的目的:
- 评估selatogrel,一种新的P2Y12抗剂,用于急性冠状动脉综合征 (ACS) 管理.
- 评估selatogrel在快速,医院前,自我治疗中的潜力.
主要方法:
- 塞拉托格雷尔是一种新型的,选择性的P2Y12受体抗剂.
- 通过皮下施用,它提供了立即干预.
- 一期和二期试验已经完成;三期试验正在进行中.
主要成果:
- 塞拉托格雷尔表现出迅速开始起作用.
- 它具有有利的安全概况.
- 在ACS患者中有可能减少总缺血时间.
结论:
- 塞拉托格雷尔是彻底改变ACS治疗的有希望的候选人.
- 它的特性支持在前医院环境中潜在的使用.
- 进一步的第三阶段研究将完善其治疗属性.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
Peripheral Artery Disease III: Interprofessional Care
248
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
248
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
465
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
465
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.1K
Angina IV: Management
238
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
238
Venous Thrombosis III: Interprofessional Care
280
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
280

